Throughout our heritage, we have continued our commitment to innovation, with a focus for the past 7 years on developing our own product candidates in neurology and psychiatry.
|Trokendi XRTM||Epilepsy||Tentative FDA Approval|
|SPN-810||Impulsive Aggression in ADHD||Completed Phase IIb|
|SPN-812||ADHD||Completed Phase IIa|
NDA=New Drug Application; IND=Investigational New Drug (application). ADHD=attention-deficit hyperactivity disorder;